Back to Search
Start Over
Effects of dopaminergic treatment on striatal dopamine turnover in de novo Parkinson disease
- Source :
- Neurology 80(2013), 1754-1761, Neurology 80(19), 1754-1761 (2013). doi:10.1212/WNL.0b013e3182918c2d
- Publication Year :
- 2013
-
Abstract
- Objective: To evaluate the effects of levodopa and the dopamine D2 agonist cabergoline on striatal dopamine turnover estimated as the inverse of the effective dopamine distribution volume ratio (EDVR) measured by 18 F-dopa PET in de novo Parkinson disease (PD). Methods: Single-center, parallel-group, randomized, observer-blinded study of cabergoline (3 mg/day) and levodopa (300 mg/day) over 12 weeks in patients with de novo PD. Primary efficacy measure was the change of the side-to-side averaged putaminal EDVR comparing baseline and end-of-maintenance period. Results: Thirty-five out of 39 randomized patients were assigned to the primary efficacy analysis (cabergoline, n = 17; levodopa, n = 18). At the end of treatment period, mean EDVRs were significantly lower compared to baseline solely in the levodopa group (relative change −1.0 ± 13.0% in cabergoline [ p = 0.525 when compared to baseline], −8.3 ± 11.8% in levodopa group [ p = 0.006]) with a nonsignificant trend between groups (mean relative difference: 7.3% (95% confidence interval −1.2% to 15.8%; p = 0.091). There was significant clinical improvement in both groups at 12 weeks compared to baseline, but no significant differences between groups in clinical and PET secondary outcome measures. Both pharmacologic treatments and PET scanning were well-tolerated and safe. Conclusion: Putaminal dopamine turnover is increased by levodopa treatment in de novo PD. The nonsignificant trend toward a larger influence by levodopa compared to cabergoline is supported by ancillary statistical analyses. This augmentation of early compensatory events by levodopa might contribute not only to its symptomatic effects, but also to its induction of motor complications.
- Subjects :
- Male
drug effects [Corpus Striatum]
Dopamine
therapeutic use [Dopamine Agonists]
law.invention
Antiparkinson Agents
Levodopa
Randomized controlled trial
law
Medicine
Single-Blind Method
metabolism [Dopamine]
Prospective Studies
pharmacology [Levodopa]
Prospective cohort study
Aged, 80 and over
Dopaminergic
Parkinson Disease
Middle Aged
pharmacology [Ergolines]
pharmacology [Dopamine Agonists]
Treatment Outcome
Dopamine Agonists
Female
diagnosis [Parkinson Disease]
medicine.drug
Agonist
Adult
medicine.medical_specialty
Cabergoline
medicine.drug_class
Urology
metabolism [Parkinson Disease]
therapeutic use [Levodopa]
Dopamine receptor D2
Humans
ddc:610
Ergolines
therapeutic use [Antiparkinson Agents]
Aged
pharmacology [Antiparkinson Agents]
business.industry
metabolism [Corpus Striatum]
drug therapy [Parkinson Disease]
Corpus Striatum
therapeutic use [Ergolines]
Neurology (clinical)
business
Subjects
Details
- Language :
- English
- Database :
- OpenAIRE
- Journal :
- Neurology 80(2013), 1754-1761, Neurology 80(19), 1754-1761 (2013). doi:10.1212/WNL.0b013e3182918c2d
- Accession number :
- edsair.doi.dedup.....0bf95de6b93241e3b29f02002b8879bb
- Full Text :
- https://doi.org/10.1212/WNL.0b013e3182918c2d